A Comparison Between Bevacizumab and Mitomycin C in Treatment of Primary Pterygium

Nassar, Alaraby Abd Elghany; Eldin, Abd Elmagid M Tag; Ashour, Khalid Fathy Abd Elnaby

doi:10.21608/ejhm.2019.44528

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, there no statistically significant difference between the two groups regarding pre-operative examination. This was in line with the study by Nassar et al, [6] who reported that the two studied groups were statistically comparable as regard main complain and the Side of pterygium in addition to the pre-treatment eye examinations. Also, in agreement with our results the study by Hwang and Choi, [7] reported that there was no statistically significant difference between the studied groups regarding laterality, preoperative pterygium grade, or horizontal distance from the corneal limbus to the pterygium head among the groups.…”

Section: Discussionsupporting

confidence: 92%

“…Regarding recurrence among the studied groups, our results showed that after one month was significantly higher in group 2 compared to group 1 (p>0.001) while there were not significantly differences between the two groups regarding recurrence after 1 week, after 3 months and after 6 months (p>0.05). Disagree to us, the study by Nassar et al, [6], reported that the pterygium recurred in 7 cases (35%) out of 20 cases. The recurrence in bevacizumab group occurred in 6 cases (60%) out of 10 cases.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Pterygium Excision with Application of Mitomycin C in Comparison to Sub-Pterygium Injection of Avastin without Excision

2023

Al-Azhar University Journal of Virus Researches and Studies

View full text Add to dashboard Cite

Pterygium is an ocular surface degenerative lesion presenting as a wing shaped fibrovascular conjunctival growth. It is located at the interpalpebral region of the conjunctiva, mostly nasal and extends to the cornea. Its prevalence has been reported to range from 0.3 to 29% and is mainly found in the tropical region. To discuss the outcomes and benefits for the patient in the treatment of the pterygium by excision and application of mitomycin C and subpterygium avastin injection without excision. The study was conducted from July 2021 till July 2022 in the Ophthalmology department of Al-Zahraa University Hospital. 40 patients who visited Ophthalmology Department at Al-Zahraa University Hospital will be included in the study. The clinical study was approved by the Azhar's University ethics committee. The follow up of all patients was done 1 week, 1 month, 3 months and 6 months postoperatively. Every follow up we examine BCVA, autorefraction, K reading. In our study we found that there is no dangerous complication in two methods of treatment however discomfort and hyperemia after 1 weeks was in all cases of group (1). Also, we found that Recurrence after one month was significantly higher in group 2. There were no significant differences between the two groups as regards the BCVA after 1, 3 and 6 months. The application of mitomycin C in comparison to sub pterygium injection of Avastin without excision are safe treatments. The two method was associated with low recurrence rates, but the use of Avastin without excision is superior in terms of complications as the mitomycin C was applied after an operation. All cases experienced discomfort after Surgery and Hyperemia for 1 week. Further comparative studies with larger sample size and longer follow up are needed to confirm the current results.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 88%

Pterygium Excision with Application of Mitomycin C in Comparison to Sub-Pterygium Injection of Avastin without Excision

2023

Al-Azhar University Journal of Virus Researches and Studies

View full text Add to dashboard Cite

show abstract

“…However, the recurrence rates vary between the different groups in some studies. For example, in a study conducted by Nassar et al [24], a signi cant recurrence rate was observed in the bevacizumab group (60%) compared to the MMC group (10%).…”

Section: Discussionmentioning

confidence: 93%

“…Statistical analysis: The sample size was calculated based on the ndings of the study by Nassar et al [24] based on the outcome of pterygium recurrence in patients. Due to the existence of 3 groups, 13 patients were multiplied by 1.4, resulting in a sample size of 19 people in each group; however, the nal sample size was determined to be 63 patients (21 individuals in each group) considering a dropout rate of 10%.…”

Section: Methodsmentioning

confidence: 99%

A comparative study of the recurrence rate and complications between mitomycin-C, interferon alpha-2b, and bevacizumab after primary pterygium surgery

Gharaee,

Varshovi-Jaghargh,

Momtahan

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose To compare subconjunctival bevacizumab injection, interferon (IFN) alpha-2b administration, and intraoperative mitomycin-C (MMC) administration as adjuvants for reducing the recurrence rate and postoperative complications following pterygium surgery. Methods This experimental comparative study involving a double-blinded clinical trial included 63 consecutive patients with primary pterygium who were surgically treated with free conjunctival autograft surgery. In addition to surgical excision, the patients were divided into three groups and treated with subconjunctival bevacizumab (10 mg/ml), subconjunctival IFN alpha-2b, or subconjunctival MMC (0.02 mg/ml). Postoperative outcomes were clinically followed up for 12 months. The main outcomes were the recurrence rate and postoperative complications. Results There was no significant difference in the recurrence rate among the three groups. In the bevacizumab group, conjunctival congestion was significantly greater than that in the other groups. No other serious complications were observed in the IFN or MMC groups. Conclusion The intraoperative administration of subconjunctival bevacizumab, IFN alpha-2b, and MMC as adjuvants is equally effective at reducing the rate of pterygium recurrence following excision. No significant difference was found in postoperative complications between these three adjuvants.

show abstract

5-Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite

Lee

Sidhu²,

Francis³

et al. 2022

The Ocular Surface

View full text Add to dashboard Cite

A Comparison Between Bevacizumab and Mitomycin C in Treatment of Primary Pterygium

Cited by 3 publications

References 9 publications

Pterygium Excision with Application of Mitomycin C in Comparison to Sub-Pterygium Injection of Avastin without Excision

Pterygium Excision with Application of Mitomycin C in Comparison to Sub-Pterygium Injection of Avastin without Excision

A comparative study of the recurrence rate and complications between mitomycin-C, interferon alpha-2b, and bevacizumab after primary pterygium surgery

5-Fluorouracil in primary, impending recurrent and recurrent pterygium: Systematic review of the efficacy and safety of a surgical adjuvant and intralesional antimetabolite

Contact Info

Product

Resources

About